Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zhongzhi Pharmaceutical Holdings Limited ( (HK:3737) ) has issued an announcement.
Zhongzhi Pharmaceutical Holdings Limited, a Cayman-incorporated pharmaceutical group listed in Hong Kong under stock code 3737, has a board structure that includes executive, non-executive and independent non-executive directors. As a listed issuer on the Hong Kong Stock Exchange, its corporate governance and shareholder arrangements are defined by its memorandum and articles of association.
The company plans to amend and restate its memorandum and articles of association to align with updated Hong Kong listing and regulatory requirements, including new regimes for treasury shares, paperless listings and uncertificated securities. The changes are also intended to facilitate more efficient corporate administration, such as enabling hybrid and virtual general meetings, and will be put to shareholders for approval by special resolution at the forthcoming annual general meeting.
A circular detailing the proposed changes and convening the annual general meeting will be sent to shareholders in due course. If approved, the amended and restated constitutional documents are expected to modernise Zhongzhi Pharmaceutical’s governance framework and operational flexibility in line with evolving market infrastructure and regulatory standards.
The most recent analyst rating on (HK:3737) stock is a Buy with a HK$0.78 price target. To see the full list of analyst forecasts on Zhongzhi Pharmaceutical Holdings Limited stock, see the HK:3737 Stock Forecast page.
More about Zhongzhi Pharmaceutical Holdings Limited
Zhongzhi Pharmaceutical Holdings Limited is a Hong Kong-listed company incorporated in the Cayman Islands and engaged in the pharmaceutical sector. The group operates under stock code 3737 and is overseen by a board comprising executive, non-executive and independent non-executive directors, reflecting a typical Hong Kong-listed corporate governance structure.
The company focuses on pharmaceutical products and related healthcare activities, targeting markets accessible via the Hong Kong capital market. Its operations are framed by the regulatory requirements of the Hong Kong Stock Exchange, and its governance and capital structure are shaped through its memorandum and articles of association as a listed issuer.
Average Trading Volume: 657,629
Technical Sentiment Signal: Hold
Current Market Cap: HK$719.9M
See more data about 3737 stock on TipRanks’ Stock Analysis page.